{"texts": ["OSUWMC Clinical Practice Guideline\nJune 2024\nAcute Asthma Exacerbations in Adults:\nEmergency Department and Inpatient Management\nWhat You Need to Know\n\u2022\nShort acting bronchodilators and systemic steroids should be started promptly upon recognition of asthma exacerbation\n\u2022\nUtilize RT-directed bronchodilator protocol for asthma exacerbations\n\u2022\nMonitor peak expiratory flow (PEF) at baseline and subsequently to help determine severity of exacerbation and response to therapy\n\u2022\nPatients should be discharged on a controller therapy and asthma action plan with close follow up\n\u2022\nClinicians can refer to OSUMC Outpatient Asthma guideline\nWhat You Need to Know\n\u2022\nShort acting bronchodilators and systemic steroids should be started promptly upon recognition of asthma exacerbation\n\u2022\nUtilize RT-directed bronchodilator protocol for asthma exacerbations\n\u2022\nMonitor peak expiratory flow (PEF) at baseline and subsequently to help determine severity of exacerbation and response to therapy\n\u2022\nPatients should be discharged on a controller therapy and asthma action plan with close follow up\n\u2022\nClinicians can refer to OSUMC Outpatient Asthma guideline\nAn asthma exacerbation is an acute or subacute episode of worsening shortness of breath, coughing, wheezing, or chest tightness.\nDetermine risk and severity. Do not delay treatment.\n\u2022\nRT evaluate patient; initiate RT-directed bronchodilator protocol for Asthma\n\u2022\nStart short-acting bronchodilators promptly\no\nAlbuterol-Ipratropium (DuoNeb) shown to reduce hospital admission in ED\nand pre-hospital setting\n\u2022\nRecommend Prednisone 40-60 mg\no\nMethylprednisolone IV 1 mg/kg (max dose 80 mg) can be used for severe\nexacerbation or if not tolerating PO\no\nNo benefit from higher steroid dose\n\u2022\nAdminister/wean supplemental oxygen to maintain SpO2 > 90%\n\u2022\nRegularly monitor PEF until clear response to therapy, plateau reached, or clinical\nchange\n\u2022\nED patients: determine disposition within 4 hours\n\u2022\nInpatients\no\nContinue or step up home controller therapy with appropriate formulary\nsubstitutions\no\nConsider pulmonary consult for patient with moderate to severe\nexacerbations or > 2 exacerbations in 12 months\nInitial Management\n\u2022\nRecommend measuring peak\nexpiratory flow (PEF)\no\nPEF can be regularly\nmonitored until clear\nresponse to therapy or\nplateau reached\n\u2022\nConsider chest x-ray if alternate\ndiagnosis suspected or no response to\ntreatment\n\u2022\nObtain venous blood gas\no\nConsider obtaining arterial\nblood gas if PEF <50% \npredicted, no response to \nroutine therapy, or further\ndecompensation\n\u2022\nEvaluate for complicating factors \no\nAnaphylaxis, pneumonia, pneumothorax\n\u2022\nConsider alternate diagnosis \no\nLaryngeal obstruction, inhaled foreign body,\nheart failure, pulmonary embolism\n\u2022\nDetermine patient\u2019s fluid balance: consider dehydration \ndue to poor oral intake, insensible losses\nFactors for Severe Asthma and Risk of Death\n\u2022\nHistory of severe exacerbations (ICU admission,\nintubation)\n\u2022\nFrequent ED visits or hospitalizations w/in past 12 months\n\u2022\nUsing > 2 canisters of albuterol/month\n\u2022\nDifficulty perceiving asthma symptoms or severity\n\u2022\nLow socioeconomic status\n\u2022\nConcomitant psychiatric illness\n\u2022\nCardiovascular, other chronic lung comorbidities\nStratify exacerbation severity (mild, moderate, severe, or life-threatening)\nFocused H&P\nTesting\nDyspnea \nMild\u2d15\nAccessory muscle use \nWheezing \nHR/Pulsus paradoxus \nPEF % predicted or % personal best\nSaO2/SpO2 on baseline O2 \nWith exertion; can speak sentences\nNone; increased RR\nOften only end expiratory\nNormal/None present\n>70%\n>95%\nModerate\u2d15\nAt rest; speaking phrases\nRetractions may be present; increased RR\nLoud, throughout exhalation\n100-120/May be present (10-25 mm Hg)\n50-69%\n90-95%\nSevere\u2d15\nAt rest; sitting upright; speaking only \nwords\nSubcostal, intercostal, or suprasternal \nretractions usually present; increased RR\nLoud, biphasic wheezing \n(inhalation and exhalation)\n>120/Often present and >25 mm Hg\n<40%\n<90%\nLife-Threatening\u2d15\nPatient is drowsy or confused\nParadoxical thoracoabdominal \nmovement\nAbsence of wheezing/breath sounds \n(silent chest)\nCan be significantly tachycardic or \nbradycardic\n<25% if obtained\n<90%\nCriteria\nCopyright \u00a92024. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial entity) \nresearch use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio State \nUniversity Technology Commercialization Office. Requests can be directed to Technology Commercialization Office (TCO) or email innovate@osu.edu.\nCopyright \u00a92024. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial entity) \nresearch use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The Ohio State \nUniversity Technology Commercialization Office. Requests can be directed to Technology Commercialization Office (TCO) or email innovate@osu.edu.\n", "Mild Asthma \nExacerbation\u2d15 \n\u2022\nInitiate RT Bronchodilator\nProtocol at Acuity Level 3\n\u2022\nPrednisone 40-60 mg daily x 5\ndays (or IV equivalent)\n\u2022\nInitiate RT Bronchodilator\nProtocol at Acuity Level 3\n\u2022\nPrednisone 40-60 mg daily x 5\ndays (or IV equivalent)\nModerate Asthma \nExacerbation\u2d15 \n\u2022\nInitiate RT Bronchodilator Protocol at\nAcuity Level 2\n\u2022\nPrednisone 40-60 mg daily x 5 days (or\nIV equivalent)\n\u2022\nIV magnesium 2 g over 20 minutes \n\u2022\nInitiate RT Bronchodilator Protocol at\nAcuity Level 2\n\u2022\nPrednisone 40-60 mg daily x 5 days (or\nIV equivalent)\n\u2022\nIV magnesium 2 g over 20 minutes \nSevere/Life-Threatening Asthma \nExacerbation\u2d15 \n\u2022\nInitiate RT Bronchodilator Protocol Acuity Level 1\n\u2022\nConsult Pulmonology and prepare for MICU\nadmission\n\u2022\nMethylprednisolone 1 mg/kg (max 80 mg) daily x 5\ndays\n\u2022\nIV magnesium 2 g over 20 minutes \n\u2022\nInitiate RT Bronchodilator Protocol Acuity Level 1\n\u2022\nConsult Pulmonology and prepare for MICU\nadmission\n\u2022\nMethylprednisolone 1 mg/kg (max 80 mg) daily x 5\ndays\n\u2022\nIV magnesium 2 g over 20 minutes \nGood \nresponse\n\u2022\nContinued need for\nsupplemental oxygen \n\u2022\nContinued increased work of\nbreathing\n\u2022\nNeed for albuterol more \nfrequently than Q4 hours \n\u2022\nFailed outpatient systemic\nsteroids \n\u2022\nAppears well but history of\nsevere exacerbations or\nconcern for further decline\n\u2022\nClinically improving but\nrequires albuterol Q4 hours\n\u2022\nPeak flow < 70% but otherwise \nimproving \n\u2022\nEconomic barriers requiring\nSW/CM evaluation\nConsider one or more of the following status \nasthmaticus adjuvant therapies:\n\u2022\nIV magnesium 2 g over 20 minutes\n\u2022\nAdminister albuterol 10-15 mg/h continuously\n\u2022\nUse NiPPV if intubation not imminently required\no\nAvoid if patient altered, encephalopathic,\nagitated, or vomiting\n\u2022\nAdminister Heliox continuously (only in patient on < \n30% FiO2)\no\nGive albuterol in line with Heliox\no\nCan be given through NRB, HHFNC, or\ncritical care (e.g., Avea) ventilator via NiPPV\nor IMV\n\u2022\nConsider epinephrine 0.3-0.5 mg SQ or IM\n\u2022\nMethylxanthines (e.g., aminophylline) not\nrecommended\n\u2022\nConsider intubation for the following:\no\nDo not respond to adjuvant therapies or\nNiPPV\no\nDevelop altered mental status or\nhemodynamic instability\n\u2022\nConsider ketamine for induction and post intubation \nsedation \n\u2022\nCAUTION: maintain a HIGH threshold for intubation;\ninvolve Pulm/CC EARLY\nGood \nresponse\nGood response\nDischarge (page 3)\nAdmit to appropriate level of \ncare (LoC Guidelines)\n\u2022\nConsider for patients with \nhigh-risk features or previous \nnear-fatal event.\n\u2022\nConsider PCU if requiring\nfrequent treatments/\nassessments, or intermittent\nNiPPV\n\u2022\nConsider Hospital at Home \nfor patients with improving\nresponse\nAdmit to appropriate level of \ncare (LoC Guidelines)\n\u2022\nConsider for patients with \nhigh-risk features or previous \nnear-fatal event.\n\u2022\nConsider PCU if requiring\nfrequent treatments/\nassessments, or intermittent\nNiPPV\n\u2022\nConsider Hospital at Home \nfor patients with improving\nresponse\n\u2022\nPatients with \no\nPersistent respiratory distress \no\nAltered mental status, apparent fatigue or\nexhaustion \no\nContinuous albuterol or Heliox\no\nContinuous NiPPV, HHFNC or IMV\n\u2022\nNormal PCO2 on blood gas is a sign of impending\nrespiratory failure. Pursue higher level of care\n\u2022\nDiscretion of ED, inpatient, and pulmonary/ICU\nteams\nPatient Admitted to ICU\nClinician discretion: \nConsider admit to ED Obs Unit \nor Hospital at Home\n\u2022\nWhen evaluating \u201cGood response\u201d, can consider:\no PEF increase by >20%\no Ability to lie flat\no Decrease in respiratory rate by 10% - 20%\no Improvement in work of breathing/decreased accessory muscle use \no Decreased in modified BORG dyspnea score\no Room air SpO2 >94% \n\u2022\nAntibiotics not routinely recommended unless concomitant infection suspected\n\u2022\nTherapies can lead to further tachycardia and hypotension; consider\nhypovolemia; give IV fluid resuscitation \n\u2022\nAvoid sedative, anxiolytic and hypnotic drugs: associated with avoidable death\n\u2022\nMonitor electrolytes, especially K+; replace as needed\n\u2022\nLactate may be elevated in setting of beta agonist use\n\u2022\nConsider inpatient pulmonary consultation for patients with slower than\nexpected clinical improvement, multiple admissions, risk factors for life-\nthreatening asthma, or clinician concerns\nNOTES\nPrepare for ICU Admission\nRecommend early discussion with pulmonary consult/\nMICU (page pulmonary/MICU fellow on call) \nCondition \nworsening\nDischarge planning (page 3)\nCopyright \u00a92024. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial \nentity) research use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The \nOhio State University Technology Commercialization Office. Requests can be directed to Technology Commercialization Office (TCO) or email innovate@osu.edu.\nCopyright \u00a92024. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded by a commercial \nentity) research use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any form without a written agreement with The \nOhio State University Technology Commercialization Office. Requests can be directed to Technology Commercialization Office (TCO) or email innovate@osu.edu.\n2\nIncomplete\nresponse\nIncomplete\nresponse\nPoor Response / \nFailure to Improve\n", "3 \n \nCopyright \u00a92024. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT \nfunded by a commercial entity) research use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any \nform without a written agreement with The Ohio State University Technology Commercialization Office. Requests can be directed to Technology \nCommercialization Office (TCO) or email innovate@osu.edu. \nDischarge \nDischarge criteria \u2013  \nper physician\u2019s discretion \nUpon discharge \n\u2022 \nPeak flow > 70% \n\u2022 \nTolerating q4 self MDI with \nspacer \n\u2022 \nOff supplemental oxygen \n\u2022 \nAble to tolerate oral \nsteroids  \n\u2022 \nImprovement in pulmonary \nexam, respiratory rate, and \nwork of breathing  \n\u2022 \nAble to demonstrate \nappropriate technique, \nasthma action plan \ncompleted \n\u2022 \nAccess to controller inhaler, \nreliever inhaler, and oral \nsteroids \n\u2022 \nDischarge from ED/CDU or LOS <24 hours: Continue albuterol MDI with spacer scheduled q4h \nwhile awake for the next 24-48 hours, and resume PRN afterwards   \n\u2022 \nContinue prednisone course for total of 5-7 days  \no \nConsider prednisone taper over 2 weeks for patients with severe or frequent exacerbations  \n\u2022 \nFor those not on long-term controller therapy, recommend initiation of inhaled corticosteroid \n(refer to Outpatient Asthma guideline). \n\u2022 \nFor those on long term therapy, consider symptom frequency and step-up therapy (refer to \nOutpatient Asthma guideline) \n\u2022 \nRecommend patient education including asthma education, inhaler technique, and \nenvironmental control measures \n\u2022 \nAsthma action plan*** dot phrase in discharge instructions and reviewed with MD/RN/RT \n\u2022 \nIf deemed high risk for readmission and delayed outpatient follow-up or no primary care \nprovider, consider scheduled follow-up in 24-48 hours in Advanced Urgent Care Center \n\u2022 \nClose follow up with asthma provider within 4-6 weeks  \n\u2022 \nConsider pulmonary referral if frequent exacerbations or uncontrolled symptoms \n\u2022 \nIf deemed appropriate for Hospital at Home program, consider consult to initiate assessment  \n \nMedications / Treatment \nMedication \nDosing \nAdverse Effects \nComments \nCorticosteroids \n\u2022 Prednisone (PO) \n\u2022 Methylprednisolone \n(IV) \nBased on severity (see \nguideline above) \n \n \n\u2022 Agitation/Delirium \n\u2022 Hyperglycemia* \n\u2022 Insomnia \n\u2022 Infection risk \n\u2022 Steroid therapy should be continued until patient \nachieves substantial symptom improvement or \nresolution \n\u2022 Steroid doses greater than those listed above have \nnot been associated with improved outcomes in \npatients with acute asthma exacerbations \n\u2022 Early administration of steroids (<1 hour of ED \npresentation) is associated with a decreased need \nfor hospital admission \nEquivalent doses \n\u2022 Prednisone: 5 mg \n\u2022 Methylprednisolone: \n4 mg \n\u2022 Dexamethasone: 0.75 \nmg \nMagnesium (IV) \n2 g over 20 minutes \nMay repeat dose once \nafter 30 minutes \n\u2022 Nausea \n\u2022 Headache \n\u2022 Hypotension \n\u2022 No need to check magnesium levels \n\u2022 Caution in patients with severe renal dysfunction \nEpinephrine (IM or SQ) \n0.3 \u2013 0.5 mg  \nMay repeat dose every \n20 minutes for three \ndoses \n\u2022 Tachycardia \n\u2022 Hypertension \n\u2022 Arrhythmias \n\u2022 Rarely, inhaled beta agonists may not be effective \nin patients with severe bronchospasm; consider \nsystemic therapy \nKetamine (IV) \nSee OSUWMC Pharmacy \nKetamine IV Guidelines \n\u2022 Sedation \n\u2022 Increased \nsecretions \n\u2022 Psychosis \n\u2022 Hypertension \n\u2022 Pulmonology/critical care does not recommend \nthe use of IV ketamine in non-intubated patients \nwith acute asthma exacerbations \n\u2022 Consider ketamine for induction and post-\nintubation sedation \nMethylxanthines \nDiscuss with clinical \npharmacy specialist \n\u2022 Vomiting \n\u2022 Arrhythmias \n\u2022 Seizures \n \n\u2022 Literature does not support the use of \nmethylxanthines in acute asthma exacerbations \n\u2022 Initiation should be done in conjunction with \npulmonology/critical care \nNotes:  \nSee Outpatient Asthma Evaluation and Management guideline for guidance on OSUWMC formulary-approved inhaler equivalency \nmedications.   \nSee Steroid-Induced Hyperglycemia Management guideline for assistance. \n", "4 \n \nCopyright \u00a92024. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded \nby a commercial entity) research use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any form without \na written agreement with The Ohio State University Technology Commercialization Office. Requests can be directed to Technology Commercialization Office \n(TCO) or email innovate@osu.edu. \nReferences \n\uf0a7 \nManser R, Reid D, Abramson M. Corticosteroids for \nacute severe asthma in hospitalised patients. \nCochrane Database Syst Rev. 2001;1:CD001740 \n\uf0a7 \nMcFadden ER. Acute severe asthma. Am J Respir Crit \nCare Med. 2003;168(7):740-759. \n\uf0a7 \nRowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota \nGW. Early emergency department treatment of acute \nasthma with systemic corticosteroids. Cochrane \nDatabase Syst Rev. 2001;(1):CD002178. \n\uf0a7 \nNair P, Milan SJ, Rowe BH. Addition of intravenous \naminophylline to inhaled beta(2)-agonists in adults \nwith acute asthma. Cochrane Database Syst Rev. \n2012;12(12):CD002742. \n\uf0a7 \nGINA: https://ginasthma.org/wp-\ncontent/uploads/2022/07/GINA-Main-Report-2022-\nFINAL-22-07-01-WMS.pdf  \n\uf0a7 \nNational Asthma Education and Prevention Program. \nExpert Panel Report 3 (EPR-3): Guidelines for the \nDiagnosis and Management of Asthma-Summary \nReport 2007. J Allergy Clin Immunol. 2007 Nov;120(5 \nSuppl):S94-138. doi: 10.1016/j.jaci.2007.09.043. \nErratum in: J Allergy Clin Immunol. 2008 \nJun;121(6):1330. PMID: 17983880. \n\uf0a7 \nFanta CH, Rossing TH, McFadden ER Jr. Glucocorticoids \nin acute asthma. A critical controlled trial. Am J Med. \n1983 May;74(5):845-51. doi: 10.1016/0002-\n9343(83)91076-8. PMID: 6340496. \n\uf0a7 \nKrishnan JA, Davis SQ, Naureckas ET, Gibson P, Rowe \nBH. An umbrella review: corticosteroid therapy for \nadults with acute asthma. Am J Med. \n2009;122(11):977-991. \ndoi:10.1016/j.amjmed.2009.02.013 \n\uf0a7 \nMcFadden ER Jr. Acute severe asthma. Am J Respir Crit \nCare Med. 2003 Oct 1;168(7):740-59. doi: \n10.1164/rccm.200208-902SO. PMID: 14522812. \n\uf0a7 \nKew KM, Kirtchuk L, Michell CI. Intravenous \nmagnesium sulfate for treating adults with acute \nasthma in the emergency department. Cochrane \nDatabase Syst Rev. 2014 May 28;(5):CD010909. doi: \n10.1002/14651858.CD010909.pub2. PMID: 24865567. \n\uf0a7 \nSelf TH, Redmond AM, Nguyen WT. Reassessment of \ntheophylline use for severe asthma exacerbation: is it \njustified in critically ill hospitalized patients? J Asthma. \n2002 Dec;39(8):677-86. doi: 10.1081/jas-120015790. \nPMID: 12507187. \n\uf0a7 \nGoyal S, Agrawal A. Ketamine in status asthmaticus: A \nreview. Indian J Crit Care Med. 2013;17(3):154-161. \ndoi:10.4103/0972-5229.117048 \n\uf0a7 \nGlobal Initiative for Asthma. Global strategy for \nasthma management and prevention. \nwww.ginasthma.org. Date last updated: 2021 \n\uf0a7 \nKress JP, Noth I, Gehlbach BK, et al. The utility of \nalbuterol nebulized with heliox during acute asthma \nexacerbations. Am J Respir Crit Care Med. \n2002;165(9):1317-1321.  \n\uf0a7 \nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166\n064/ \n\uf0a7 \nhttps://www.atsjournals.org/doi/full/10.1164/rccm.9\n907035 \n \nOSUWMC Resources \n\uf0a7 \nOutpatient Asthma Clinical Practice Guideline \n\uf0a7 \nAdvanced Noninvasive Respiratory Support Guideline \n\uf0a7 \nAsthma Assessment and scoring tool \n\uf0a7 \nRespiratory Therapy-Directed Asthma and COPD \nInhaler Protocol \n\uf0a7 \nHeliox Policy  \n\uf0a7 \nNon-invasive Mechanical Ventilation (NIMV) Policy  \n\uf0a7 \nPeak flow calculator male \n\uf0a7 \nPeak flow calculator female    \n\uf0a7 \nLevel of Care Guidelines \n \nQuality Measures \n\uf0a7 \nAll patients with asthma discharged with rescue \ninhaler included on medication list \n\uf0a7 \nAll patients with persistent asthma discharged with \ncontroller therapy included on medication list \n\uf0a7 \nPCP or Pulmonary follow-up arranged within 2-6 \nweeks of an asthma related hospitalization \n \nOrder Sets \n\uf0a7 \nIn development \n \nAuthors \n\uf0a7 \nMegan Conroy, MD, MA(Ed), FCCP \n\uf0a7 \nAllison Rossetti, MD, FACP, FAAP \n\uf0a7 \nEric Adkins, MD \n\uf0a7 \nJosh Arnold, PharmD, BCCCP \n\uf0a7 \nRyan Bellomy, RRT, RCP \n\uf0a7 \nMatthew Curtis, RRT, RCP \n\uf0a7 \nScott Hazelwood, RRT, RCP, MRT \n\uf0a7 \nAkshay Vijayaraman, MD \n\uf0a7 \nAngad Sodhi, PharmD \n\uf0a7 \nTiffany Moore-Shook, MRT, RRT, RCP \n\uf0a7 \nMichael Purcell, MD \n\uf0a7 \nJamie Zimmer, RRT, RCP \n \nGuideline reviewed by: Critical Care Quality Management \nCommittee \n \nGuideline Approved \nJune 31, 2024. First Edition. \n \n", "5 \n \nCopyright \u00a92024. The Ohio State University. All rights reserved. This document may be used for noncommercial educational and noncommercial (NOT funded \nby a commercial entity) research use only. OSUWMC Clinical Practice Guidelines may not be reproduced, displayed, modified, or distributed in any form without \na written agreement with The Ohio State University Technology Commercialization Office. Requests can be directed to Technology Commercialization Office \n(TCO) or email innovate@osu.edu. \nDisclaimer: Clinical practice guidelines and algorithms at \nThe Ohio State University Wexner Medical Center \n(OSUWMC) are standards that are intended to provide \ngeneral guidance to clinicians. Patient choice and clinician \njudgment must remain central to the selection of \ndiagnostic tests and therapy. OSUWMC\u2019s guidelines and \nalgorithms are reviewed periodically for consistency with \nnew evidence; however, new developments may not be \nrepresented. \n"], "metadatas": [{"source": "predefined-pdfs/AsthmaInpatient.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T00:30:11.727936", "filename": "AsthmaInpatient.pdf"}, {"source": "predefined-pdfs/AsthmaInpatient.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T00:30:11.727963", "filename": "AsthmaInpatient.pdf"}, {"source": "predefined-pdfs/AsthmaInpatient.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T00:30:11.727967", "filename": "AsthmaInpatient.pdf"}, {"source": "predefined-pdfs/AsthmaInpatient.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T00:30:11.727970", "filename": "AsthmaInpatient.pdf"}, {"source": "predefined-pdfs/AsthmaInpatient.pdf", "type": "predefined_document", "content_type": "text", "timestamp": "2025-01-16T00:30:11.727973", "filename": "AsthmaInpatient.pdf"}]}